Literature DB >> 15710571

Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia.

Stefan Fröhling1, Sabine Kayser, Cora Mayer, Simone Miller, Christa Wieland, Silvia Skelin, Richard F Schlenk, Hartmut Döhner, Konstanze Döhner.   

Abstract

BACKGROUND AND OBJECTIVES: Karyotype is one of the most important prognostic factors in acute myeloid leukemia (AML). DESIGN AND METHODS: To assess the diagnostic value of molecular cytogenetics in AML patients older than 60 years, we compared the results of chromosome banding with those of fluorescence in situ hybridization (FISH) applying a comprehensive DNA-probe set for the detection of the most relevant AML-associated chromosome aberrations in a prospective series of 283 patients registered for the multicenter treatment trial AML HD98-B.
RESULTS: Four cases of inv(16)/t(16;16) and 2 cases of t(11q23) were only detected by FISH. Molecular cytogenetic analysis was also more sensitive for the detection of genomic imbalances, in particular 7q-, +11q, 17p-, and 20q-, but virtually all cases of aneuploidy or deletions that were missed on banding analysis were identified in patients without assessable metaphases, in patients with normal karyotypes but poor chromosome morphology, in patients with a leukemia-specific balanced rearrangement, or in patients with complex karyotypes. INTERPRETATION AND
CONCLUSIONS: Our results support the use of FISH as a complementary method for the detection of inv(16)/t(16;16) and t(11q23) in all older AML patients eligible for intensive therapy. Molecular cytogenetics should also be considered in cases with insufficient yields of metaphase cells, poor chromosome morphology, or both. Routine screening for chromosomal imbalances by FISH does not improve cytogenetic risk assessment in patients with adequate pretreatment karyotype information.

Entities:  

Mesh:

Year:  2005        PMID: 15710571

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.

Authors:  Gu-Sheng Tang; Jun Wu; Min Liu; Hui Chen; Shen-Glan Gong; Jian-Min Yang; Xiao-Xia Hu; Jian-Min Wang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

2.  Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Authors:  Sylvain Mareschal; Anna Palau; Johan Lindberg; Philippe Ruminy; Christer Nilsson; Sofia Bengtzén; Marie Engvall; Anna Eriksson; Anne Neddermeyer; Vinciane Marchand; Monika Jansson; My Björklund; Fabrice Jardin; Mattias Rantalainen; Andreas Lennartsson; Lucia Cavelier; Henrik Grönberg; Sören Lehmann
Journal:  Blood Adv       Date:  2021-02-23

3.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

Review 4.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.